RxDoctor Payments Data

Jennifer Chavez, PA

Surgical · Omaha, NENPI 1457354789

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 28.3% of the total. Reporting peaked in 2024 at $1,161 and has fallen 64.4% since, to $413 in 2025.

$3,227in general payments, 2019–2025

Across 123 payments — averaging $26.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$913
  • Lemaitre Vascular, Inc.$456
  • Medical Device Business Services, Inc.$255
  • Bard Peripheral Vascular, Inc.$245
  • Johnson & Johnson$241
  • Boston Scientific$151
  • plus $965 from 19 others

What the payments were for

  • Food & beverage$3,227100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,227 in reported general payments places this provider in the 85th percentile of 101 surgical providers in Nebraska.

See all surgical providers in Nebraska

Medicare billing

Part B allowed, 2024
$13,860
Medicare patients
114
Services billed
170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$8,617
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen95$1,045
ClopidogrelClopidogrel Bisulfate123$982
Gabapentin37$713
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$309
Nystatin11$172

Paid to pharmacies, not to this prescriber.

Other surgical in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →